blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2776035

EP2776035 - COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.06.2017
Database last updated on 05.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Modgene, LLC
P.O. Box 422
Cardiff by the Sea, CA 92007 / US
[2016/48]
Former [2014/38]For all designated states
Modgene, Llc
P.O.box 422
Cardiff By The Sea, CA 92007 / US
For all designated states
Sutcliffe, J. Gregor
2253 Via Tempo
Cardiff, CA 92007 / US
For all designated states
Hilbush, Brian S.
5690 Willowmere Lane
San Diego, CA 92130 / US
Inventor(s)01 / SUTCLIFFE, J. Gregor
2253 Via Tempo
Cardiff, CA 92007 / US
02 / HILBUSH, Brian S.
5 Mara Vista Ct.
Tiburon, CA 94920 / US
 [2016/48]
Former [2014/38]01 / SUTCLIFFE, J. Gregor
2253 Via Tempo
Cardiff, CA 92007 / US
02 / HILBUSH, Brian S.
5690 Willowmere Lane
San Diego, CA 92130 / US
Representative(s)Glawe, Delfs, Moll
Partnerschaft mbB von
Patent- und Rechtsanwälten
Postfach 13 03 91
20103 Hamburg / DE
[N/P]
Former [2016/32]Glawe, Delfs, Moll
Partnerschaft mbB
von Patent- und Rechtsanwälten
Postfach 13 03 91
20103 Hamburg / DE
Former [2014/38]Glawe, Delfs, Moll
Partnerschaft mbB von
Patent- und Rechtsanwälten
Rothenbaumchaussee 58
20148 Hamburg / DE
Application number, filing date12783828.201.11.2012
[2016/32]
WO2012US63025
Priority number, dateUS201161554375P01.11.2011         Original published format: US 201161554375 P
US201261682031P10.08.2012         Original published format: US 201261682031 P
[2014/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013067157
Date:10.05.2013
Language:EN
[2013/19]
Type: A1 Application with search report 
No.:EP2776035
Date:17.09.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 10.05.2013 takes the place of the publication of the European patent application.
[2014/38]
Type: B1 Patent specification 
No.:EP2776035
Date:10.08.2016
Language:EN
[2016/32]
Search report(s)International search report - published on:EP10.05.2013
ClassificationIPC:A61K31/506, A61K45/06, A61P25/06
[2016/09]
CPC:
A61K31/506 (EP,US); A61K45/06 (EP,US); A61P25/06 (EP);
A61P25/28 (EP)
C-Set:
A61K31/506, A61K2300/00 (EP,US)
Former IPC [2014/38]A61K31/506, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/38]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERRINGERUNG EINER AMYLOID-BETA-LADUNG[2014/38]
English:COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD[2014/38]
French:COMPOSITIONS ET MÉTHODES DE RÉDUCTION DE LA CHARGE AMYLOÏDE-BÊTA[2014/38]
Entry into regional phase02.06.2014National basic fee paid 
02.06.2014Designation fee(s) paid 
02.06.2014Examination fee paid 
Examination procedure02.06.2014Amendment by applicant (claims and/or description)
02.06.2014Examination requested  [2014/38]
18.11.2014Despatch of a communication from the examining division (Time limit: M04)
16.03.2015Reply to a communication from the examining division
04.08.2015Despatch of a communication from the examining division (Time limit: M04)
09.10.2015Reply to a communication from the examining division
03.03.2016Communication of intention to grant the patent
01.07.2016Fee for grant paid
01.07.2016Fee for publishing/printing paid
01.07.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.11.2014
Opposition(s)11.05.2017No opposition filed within time limit [2017/29]
Fees paidRenewal fee
26.11.2014Renewal fee patent year 03
30.11.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.11.2012
AL10.08.2016
AT10.08.2016
BE10.08.2016
CY10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
MC10.08.2016
MK10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SI10.08.2016
SK10.08.2016
SM10.08.2016
TR10.08.2016
MT01.11.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
LU30.11.2016
IS10.12.2016
PT12.12.2016
[2018/46]
Former [2018/45]HU01.11.2012
AT10.08.2016
BE10.08.2016
CY10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
MC10.08.2016
MK10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SI10.08.2016
SK10.08.2016
SM10.08.2016
TR10.08.2016
MT01.11.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
LU30.11.2016
IS10.12.2016
PT12.12.2016
Former [2018/43]HU01.11.2012
AT10.08.2016
BE10.08.2016
CY10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
MC10.08.2016
MK10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SI10.08.2016
SK10.08.2016
SM10.08.2016
MT01.11.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
LU30.11.2016
IS10.12.2016
PT12.12.2016
Former [2018/30]HU01.11.2012
AT10.08.2016
BE10.08.2016
CY10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
MC10.08.2016
MK10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SI10.08.2016
SK10.08.2016
SM10.08.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
LU30.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/45]AT10.08.2016
BE10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SI10.08.2016
SK10.08.2016
SM10.08.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
LU30.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/37]AT10.08.2016
BE10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SI10.08.2016
SK10.08.2016
SM10.08.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/23]AT10.08.2016
BE10.08.2016
CZ10.08.2016
DK10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SK10.08.2016
SM10.08.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/23]AT10.08.2016
BE10.08.2016
CZ10.08.2016
EE10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
PL10.08.2016
RO10.08.2016
RS10.08.2016
SE10.08.2016
SK10.08.2016
BG10.11.2016
NO10.11.2016
GR11.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/13]AT10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
LV10.08.2016
PL10.08.2016
RS10.08.2016
SE10.08.2016
NO10.11.2016
GR11.11.2016
BE30.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/11]AT10.08.2016
ES10.08.2016
FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
PL10.08.2016
RS10.08.2016
SE10.08.2016
NO10.11.2016
GR11.11.2016
BE30.11.2016
IS10.12.2016
PT12.12.2016
Former [2017/10]FI10.08.2016
HR10.08.2016
IT10.08.2016
LT10.08.2016
PL10.08.2016
RS10.08.2016
SE10.08.2016
NO10.11.2016
BE30.11.2016
IS10.12.2016
Former [2017/09]FI10.08.2016
IT10.08.2016
LT10.08.2016
NO10.11.2016
Former [2017/07]LT10.08.2016
Cited inInternational search[X]WO2010057020  (MODGENE LLC [US], et al) [X] 1-4,7-14,16-19,21-24 * example -; claim - *;
 [I]WO2011016861  (INTRA CELLULAR THERAPIES INC [US], et al) [I] 1-4 * example - *
 [I]  - SUTCLIFFE, G.J. ET AL., "Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease", JOURNAL OF NEUROSCIENCE RESEARCH, (201009), vol. 89, pages 808 - 814, XP002687920 [I] 1-4 * figure 2 *

DOI:   http://dx.doi.org/10.1002/JNR.22603
 [I]  - HE, G. ET AL., "Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease", NATURE, (20110303), vol. 467, pages 95 - 99, XP002687921 [I] 1-4 * figures 1,2 *

DOI:   http://dx.doi.org/10.1038/NATURE09325
by applicantUS2002128319
 US2004028673
 WO2004032925
 US5521184
 EP0564409
    - TERRY RD., J GERIATR PSYCHIATRY NEUROL, (2006), vol. 19, pages 125 - 128
    - BROOKMEYER R; JOHNSON E; ZIEGLER-GRAHAM K; ARRIGHI HM., ALZHEIMER'S DEMENT, (2007), vol. 3, pages 186 - 191
    - POWERS JM., NEUROBIOL AGING, (1997), vol. 18, pages S53 - S54
    - GIACOBINI E., ANN NY ACAD SCI, (2000), vol. 920, pages 321 - 327
    - CEDAZO-MINGUEZ A., J CELL MOL MED., (2007), vol. 11, pages 1227 - 38
    - URYU ET AL., J. NEUROSCI., (2002), vol. 22, no. 2, page 446
    - TANZI RE., ANN MED., (1989), vol. 21, pages 91 - 94
    - WOLFE MS., BIOCHEMISTRY, (2006), vol. 45, pages 7931 - 7939
    - BARTEN DM; ALBRIGHT CF., MOL NEUROBIOL, (2008), vol. 37, pages 171 - 186
    - SELKOE DJ., PHYSIOL REV, (2001), vol. 81, pages 741 - 766
    - WARING SC; ROSENBERG RN., ARCH NEUROL., (2008), vol. 65, pages 329 - 34
    - FRANCIS ET AL., DEVELOPMENTAL CELL, (2002), vol. 3, no. 1, pages 85 - 97
    - STEINER ET AL., J. BIOL. CHEMISTRY, (2002), vol. 277, no. 42, pages 39062 - 39065
    - LI ET AL., J. NEUROCHEM., (2002), vol. 82, no. 6, pages 1540 - 1548
    - ROJAS-FEMANDEZ CH; CHEN M; FERNANDEZ HL., PHARMACOTHERAPY, (2002), vol. 22, pages 1547 - 1563
    - HARDY J; SELKOE DJ., SCIENCE, (2002), vol. 297, pages 353 - 356
    - LUO Y; BOLON B; KAHN S; BENNETT BD; BABU-KHAN S; DENIS P; FAN W; KHA H; ZHANG J; GONG Y, NAT NEUROSCI, (2001), vol. 4, pages 231 - 232
    - OHNO M; CHANG L; TSENG W; OAKLEY H; CITRON M; KLEIN WL; VASSAR R; DISTERHOFT JF., EUR J NEUROSCI, (2006), vol. 23, pages 251 - 260
    - OHNO M; SAMETSKY EA; YOUNKIN LH; OAKLEY H; YOUNKIN SG; CITRON M; VASSAR R; DISTERHOFT JF., NEURON, (2004), vol. 41, pages 27 - 33
    - LAIRD FM; CAI H; SAVONENKO AV; FARAH MH; HE K; MELNIKOVA T; WEN H; CHIANG H-C; XU G; KOLIATSOS VE, J NEUROSCI, (2005), vol. 25, pages 11693 - 11709
    - DOMINGUEZ D; TOURNOY J; HARTMANN D; HUTH T; CRYNS K; DEFORCE S; SEMEELS L; CAMACHO IE; MARJAUX E; CRAESSAERTS K, J BIOL CHEM, (2005), vol. 280, pages 30797 - 30806
    - HU X; HICKS CW; HE W; WONG P; MACKLIN WB; TRAPP BD; YAN R., NAT NEUROSCI, (2006), vol. 9, pages 1520 - 1525
    - BARTEN DM; MEREDITH JE JR; ZACZEK R; HOUSTON JG; ALBRIGHT CF, DRUGS, (2006), vol. 7, pages 87 - 97
    - POLLACK SJ; LEWIS H, CURR OPIN INVESTIG DRUGS, (2005), vol. 6, pages 35 - 47
    - SEARFOSS GH; JORDAN WH; CALLIGARO DO; GALBREATH EJ; SCHIRTZINGER LM; BERRIDGE BR; GAO H; HIGGINS MA; MAY PC; RYAN TP., J BIOL CHEM, (2003), vol. 278, pages 46107 - 46116
    - WONG GT; MANFRA D; POULET FM; ZHANG Q; JOSIEN H; BARA T; ENGSTROM L; PINZON-ORTIZ M; FINE JS; LEE HJ, J BIOL CHEM, (2004), vol. 279, pages 12876 - 12882
    - TOXICOL SCI, (2004), vol. 82, pages 341 - 358
    - LANGMAN ET AL., LANCET, (1994), vol. 343, pages 1075 - 1078
    - NETZER WJ ET AL., PROC NATL ACAD SCI U S A, (2003), vol. 100, pages 12444 - 12449
    - TAKAYAMA N; SATO N; O'BRIEN SG; IKEDA Y; OKAMOTO S., BR J HAEMATOL., (2002), vol. 119, pages 106 - 108
    - FORCE, T.; KOLAJA, K. L., "Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes", NAT. REV. DRUG DISCOV., (2011), vol. 10, pages 111 - 126
    - CHU, T. F. ET AL., "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib", LANCET, (2007), vol. 370, doi:doi:10.1016/S0140-6736(07)61865-0, pages 2011 - 2019, XP022388886

DOI:   http://dx.doi.org/10.1016/S0140-6736(07)61865-0
    - CHENG, H.; FORCE, T., "Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics", CIRC. RES., (2010), vol. 106, pages 21 - 34
    - J. WANG; R.W. WILLIAMS; K.F. MANLY, NEUROINFORMATICS, (2003), vol. 1, page 299
    - D. GATTI ET AL., HEPATOLOGY, (2007), vol. 46, page 548
    - MOASSER ET AL., CANCER RESEARCH, (1999), vol. 59, pages 6145 - 6152
    - WISNIEWSKI ET AL., CANCER RESEARCH, (2002), vol. 62, no. 15, pages 4244 - 55
    - U. BICKEL, NEURORX, (200501), vol. 2, no. 1, pages 15 - 26
    - HANSCH ET AL., J. PHARM. SCI., (1987), vol. 76, no. 9, pages 663 - 687
    - VELPANDIAN ET AL., JOURNAL OF CHROMATOGRAPHY B, (2004), vol. 804, no. 2, pages 431 - 434
    - RAMIREZ ET AL., THE JOURNAL OFNEUROSCIENCE, (20050223), vol. 25, no. 8, pages 1904 - 1913
    - RS DOODY ET AL., THE LANCET, (2008), vol. 372, pages 207 - 215
    - I HAJJAR ET AL., THE JOURNALS OF GERONTOLOGY SERIES A: BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, (2005), vol. 60, pages 67 - 73
    - B FRANK ET AL., ANN CLIN PSYCHIATRY, (2005), vol. 17, no. 4, pages 269 - 86
    - NETZER WJ ET AL., PROC NATL ACAD SCI U S A., (2003), vol. 100, pages 12444 - 12449
    - GAMES D; ADAMS D; ALESSANDRINI R; BARBOUR R; BERTHELETTE P; BLACKWELL C; CARR T; CLEMENS J; DONALDSON T; GILLESPIE F ET AL., NATURE, vol. 373, pages 523 - 527
    - HSIA AY; MASLIAH E; MCCONLOGUE L; YU GQ; TATSUNO G; HU K; KHOLODENKO D; MALENKA RC; NICOLL RA; MUCKE L., PROC NATL ACAD SCI USA., (1999), vol. 96, pages 3228 - 3233
    - HSIAO K; CHAPMAN P; NILSEN S; ECKMAN C; HARIGAYA Y; YOUNKIN S; YANG F; COLE G., SCIENCE, (1996), vol. 274, pages 99 - 102
    - STURCHLER-PIERRAT C; ABRAMOWSKI D; DUKE M; WIEDERHOLD KH; MISTL C; ROTHACHER S; LEDERMANN B; BURKI K; FREY P; PAGANETTI PA, PROC NATL ACAD SCI USA, (1997), vol. 94, pages 13287 - 13292
    - MOECHARS D; DEWACHTER I; LORENT K; REVERSE D; BAEKELANDT V; NAIDU A; TESSEUR I; SPITTAELS K; HAUTE CV; CHECLER F, J BIOL CHEM., (1999), vol. 274, pages 6483 - 6492
    - RICHARDSON JC; KENDAL CE; ANDERSON R; PRIEST F; GOWER E; SODEN P; GRAY R; TOPPS S; HOWLETT DR; LAVENDER D, NEUROSCIENCE, (2003), vol. 122, pages 213 - 228
    - BUTTINI M; YU GQ; SHOCKLEY K; HUANG Y; JONES B; MASLIAH E; MALLORY M; YEO T; LONGO FM; MUCKE L., J NEUROSCI., (2002), vol. 22, pages 10539 - 10548
    - BLOOM FE; REILLY JF; REDWINE JM; WU CC; YOUNG WG; MORRISON JH., ARCH NEUROL., (2005), vol. 62, pages 185 - 187
    - KULNANE LS; LAMB BT., NEUROBIOL DIS., (2001), vol. 8, pages 982 - 992
    - LEHMAN EJ; KULNANE LS; GAO Y; PETRIELLO MC; PIMPIS KM; YOUNKIN L; DOLIOS G; WANG R; YOUNKIN SG; LAMB BT., HUM MOL GENET., (2003), vol. 12, pages 2949 - 2956
    - RYMAN D; GAO Y; LAMB BT., NEUROBIOL AGING, (2008), vol. 29, pages 1190 - 1198
    - MASLIAH, E. ET AL., "P amyloid peptides enhance a-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease", PNAS, (2001), vol. 98, doi:doi:10.1073/pnas.211412398, pages 12245 - 12250, XP002201752

DOI:   http://dx.doi.org/10.1073/pnas.211412398
    - JOHNSON-WOOD, K ET AL., "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease", PNAS, (1997), vol. 94, doi:doi:10.1073/pnas.94.4.1550, pages 1550 - 1555, XP002275435

DOI:   http://dx.doi.org/10.1073/pnas.94.4.1550
    - CHISHTI, M.A. ET AL., "Early-onset amyloid deposition and cognitive defects in transgenic mice expressing a double mutant form of amyloid precursor protein 695", J. BIOL. CHEM., (2001), vol. 276, doi:doi:10.1074/jbc.M100710200, pages 21562 - 21570, XP055163719

DOI:   http://dx.doi.org/10.1074/jbc.M100710200
    - T. KAWARABAYASHI ET AL., NEUROSCI, (2001), vol. 21, page 372
    - E.J. LEHMAN ET AL., HUM MOL GENET, (2003), vol. 12, page 2949
    - S. ISHIGAKI ET AL., BIOCHEM BIOPHYS RES COMMUN, (2002), vol. 279, page 526
    - S.R. HUSTINX ET AL., CANCER BIOL THER, (2004), vol. 3, page 1254
    - S.M. STABLER ET AL., J CELL BIOL, (1999), vol. 14, no. 145, page 1277
    - M. BLAZEJCZYK ET AL., BIOCHIM BIOPHYS ACTA, (2006), vol. 1762, page 66
    - C. WHITE ET AL., J BIOL CHEM, (2006), vol. 281, page 20825
    - K.H. CHEUNG ET AL., NEURON, (2008), vol. 58, page 871
    - G. BASSEZ ET AL., NEUROBIOL DIS, (2004), vol. 15, page 240
    - G. VERSTAPPEN ET AL., HUM MOL GENET, (2008), vol. 17, page 1175
    - N. ISOHATA ET AL., INT J CANCER, (2009), vol. 125, page 1212
    - C. ZWEIER ET AL., AM J MED GENET, (2002), vol. 108, page 177
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.